At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Pembrolizumab +3 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab, SurVaxM, and 2 other interventions for Recurrent Glioblastoma. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartMar 2020
Primary CompletionAug 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedJul 10, 2019
Enrollment StartMar 19, 2020
Primary CompletionAug 16, 2021
Study CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.0 years ago
Interventions
Pembrolizumabdrug
200 mg IV every 3 weeks
SurVaxMdrug
500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
Sargramostimdrug
100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
Montanide ISA 51drug
1 ml per dose dosed every two weeks for 4 doses and then every 3 months